- Following induction chemotherapy in older adult patients with acute myelogenous leukemia (AML) to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death. The safety and efficacy of Leukine have not been assessed in patients with AML under 55 years of age.
- For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis.
- For acceleration of myeloid recovery in patients with Non-Hodgkin's Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL), and Hodgkin's disease undergoing autologous bone marrow transplantation (BMT).
- For acceleration of myeloid recovery in patients undergoing allogeneic BMT from Human Lymphocyte Antigen (HLA)-matched related donors.
- For patients who have undergone allogeneic or autologous BMT in whom engraftment is delayed or has failed.
Coverage of drugs is first determined by the member’s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document.